dc.contributor.author | Avery, Lisa M. | |
dc.contributor.author | Steed, Molly E. | |
dc.contributor.author | Woodruff, Ashley E. | |
dc.contributor.author | Hasan, Muhammad | |
dc.contributor.author | Rybak, Michael J. | |
dc.date.accessioned | 2015-05-05T20:59:28Z | |
dc.date.available | 2015-05-05T20:59:28Z | |
dc.date.issued | 2012-11 | |
dc.identifier.citation | Avery et. al. "Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus Vertebral Osteomyelitis Cases Complicated by Bacteremia Treated with High-Dose Daptomycin and Trimethoprim-Sulfamethoxazole." Antimicrob. Agents Chemother. November 2012 vol. 56 no. 11 5990-5993 http://dx.doi.org/10.1128/AAC.01046-12 | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/17607 | |
dc.description.abstract | We report two cases of daptomycin (DAP)-nonsusceptible (DNS) vancomycin-intermediate Staphylococcus aureus (VISA) vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole. Both patients responded rapidly and favorably to this combination. The clinical isolates from the two patients were tested post hoc in an in vitro pharmacokinetic/pharmacodynamic (PK/PD) model to confirm the bactericidal activity and enhancement of daptomycin and trimethoprim-sulfamethoxazole. The combination of high-dose daptomycin and trimethoprim-sulfamethoxazole should be explored further for the treatment of DNS VISA strains. | en_US |
dc.description.sponsorship | M.J.R. has received grant support, consulted for, or provided lectures for Astellas, Cubist, Forest, Clinical Therapeutics, Theravance, and Rib- X. L.M.A has served as an advisory board member (Forest) and provided lectures (Astellas) and owns stock (Merck). M.E.S., A.E.W., and M.H. have no potential conflicts of interest. | en_US |
dc.publisher | American Society for Microbiology | en_US |
dc.title | Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus Vertebral Osteomyelitis Cases Complicated by Bacteremia Treated with High-Dose Daptomycin and Trimethoprim-Sulfamethoxazole | en_US |
dc.type | Article | |
kusw.kuauthor | Steed, Molly E. | |
kusw.kudepartment | Department of Pharmaceutical Chemistry | en_US |
dc.identifier.doi | 10.1128/AAC.01046-12 | |
kusw.oaversion | Scholarly/refereed, publisher version | |
kusw.oapolicy | This item meets KU Open Access policy criteria. | |
dc.rights.accessrights | openAccess | |